Immunome Company Leadership
| IMNM Stock | USD 13.47 1.94 16.83% |
About 60% of all Immunome's insiders are taking a long position. The analysis of the overall insider sentiment regarding Immunome suggests that some insiders are bullish. Immunome employs about 55 people. The company is managed by 17 executives with a total tenure of roughly 129 years, averaging almost 7.0 years of service per executive, having 3.24 employees per reported executive.
Immunome's Insider Buying Vs Selling
60
Selling | Buying |
Latest Trades
| 2024-11-21 | Robert Lechleider | Acquired 15805 @ 9.48 | View | ||
| 2024-09-19 | Max Rosett | Disposed 14380 @ 16.01 | View | ||
| 2024-08-16 | Jean Jacques Bienaime | Acquired 7000 @ 13.94 | View | ||
| 2024-08-15 | Jack Higgins | Disposed 3524 @ 13.93 | View | ||
| 2024-05-21 | Jean Jacques Bienaime | Acquired 2000 @ 13.57 | View |
Monitoring Immunome's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Immunome |
Immunome Management Team Effectiveness
The company has return on total asset (ROA) of (0.3989) % which means that it has lost $0.3989 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.7636) %, meaning that it created substantial loss on money invested by shareholders. Immunome's management efficiency ratios could be used to measure how well Immunome manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Tangible Assets is likely to drop to -0.75. In addition to that, Return On Capital Employed is likely to drop to -0.91. At this time, Immunome's Total Assets are very stable compared to the past year. As of the 27th of November 2024, Total Current Assets is likely to grow to about 151.9 M, while Net Tangible Assets are likely to drop about 10 M.As of the 27th of November 2024, Common Stock Shares Outstanding is likely to drop to about 11.7 M. In addition to that, Net Loss is likely to grow to about (32.1 M)
Immunome Workforce Comparison
Immunome is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,254. Immunome holds roughly 55.0 in number of employees claiming about 4% of equities under Health Care industry.
Immunome Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunome insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunome's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Immunome insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-09-01 | 2.0 | 10 | 5 | 1,898,524 | 81,899 |
| 2024-03-01 | 0.8 | 4 | 5 | 707,934 | 40,900 |
| 2023-12-01 | 1.0 | 11 | 11 | 1,662,647 | 4,127,229 |
| 2022-06-01 | 2.5 | 15 | 6 | 430,500 | 80,916 |
| 2021-09-01 | 5.0 | 5 | 1 | 74,255 | 2,343 |
| 2020-12-01 | 0.7407 | 20 | 27 | 2,286,069 | 3,375,444 |
Immunome Notable Stakeholders
An Immunome stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Immunome often face trade-offs trying to please all of them. Immunome's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Immunome's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Clay Siegall | CEO President | Profile | |
| Matthew Robinson | Chief Officer | Profile | |
| Michael Morin | Chief Scientist | Profile | |
| Philip Roberts | Chief Officer | Profile | |
| Robert Lapetina | Principal Officer | Profile | |
| JD Esq | General Officer | Profile | |
| Purnanand Sarma | CEO Pres | Profile | |
| Sandra Esq | Gen Officer | Profile | |
| Bruce MD | Chief Officer | Profile | |
| Kinney Horn | Chief Officer | Profile | |
| Corleen Roche | Chief Officer | Profile | |
| Robert MD | Chief Officer | Profile | |
| Roee Shahar | Executive Commercial | Profile | |
| Max Rosett | Principal Operations | Profile | |
| Philip Tsai | Chief Officer | Profile | |
| Dennis Giesing | Chief Officer | Profile | |
| Jack Higgins | Chief Officer | Profile |
About Immunome Management Performance
The success or failure of an entity such as Immunome often depends on how effective the management is. Immunome management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Immunome management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Immunome management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.72) | (0.75) | |
| Return On Capital Employed | (0.86) | (0.91) | |
| Return On Assets | (0.72) | (0.75) | |
| Return On Equity | (0.89) | (0.94) |
Immunome Workforce Analysis
Traditionally, organizations such as Immunome use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Immunome within its industry.Immunome Manpower Efficiency
Return on Immunome Manpower
| Revenue Per Employee | 254.9K | |
| Revenue Per Executive | 824.6K | |
| Net Loss Per Employee | 1.9M | |
| Net Loss Per Executive | 6.3M | |
| Working Capital Per Employee | 2.2M | |
| Working Capital Per Executive | 7.2M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.94) | Revenue Per Share 0.189 | Quarterly Revenue Growth (0.18) | Return On Assets (0.40) | Return On Equity (2.76) |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.